Skip to content

Clinical trials

Recruiting Precursor Cell Lymphoblastic Leukemia-Lymphoma trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Precursor Cell Lymphoblastic Leukemia-Lymphoma Status: Recruiting Country / region: United States Clear all

138 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20092
20111
20131
20142
20151
20163
20175
20183
20196
20204
20214
202213
202318
202429
202522
202623

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting138

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
St. Jude Children's Research Hospital13
City of Hope Medical Center8
National Cancer Institute (NCI)7
Fred Hutchinson Cancer Center6
M.D. Anderson Cancer Center5
Masonic Cancer Center, University of Minnesota5
Memorial Sloan Kettering Cancer Center5
University of Chicago4
Children's Hospital of Philadelphia3
Columbia University3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma138
Leukemia, Myeloid, Acute52
Myelodysplastic Syndromes36
Leukemia, Biphenotypic, Acute21
Lymphoma, Non-Hodgkin21
Leukemia, Myelogenous, Chronic, BCR-ABL Positive20
Burkitt Lymphoma18
Hodgkin Disease16
Leukemia16
Hematologic Neoplasms15

Trials

Showing 1 to 25 of 138. Each trial links to its page on Pharma Observatory.

38 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.